Changes in Cortical Cytoskeletal and Extracellular Matrix Gene Expression in Prostate Cancer Are Related to Oncogenic ERG Deregulation

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Sep 24

PMID 20860828

Citations 28

Authors

Wolfgang A Schulz

Marc Ingenwerth

Carolle E Djuidje

Christiane Hader

Jorg Rahnenfuhrer

Rainer Engers

Affiliations

Soon will be listed here.

Abstract

Background: The cortical cytoskeleton network connects the actin cytoskeleton to various membrane proteins, influencing cell adhesion, polarity, migration and response to extracellular signals. Previous studies have suggested changes in the expression of specific components in prostate cancer, especially of 4.1 proteins (encoded by EPB41 genes) which form nodes in this network.

Methods: Expression of EPB41L1, EPB41L2, EPB41L3 (protein: 4.1B), EPB41L4B (EHM2), EPB41L5, EPB49 (dematin), VIL2 (ezrin), and DLG1 (summarized as "cortical cytoskeleton" genes) as well as ERG was measured by quantitative RT-PCR in a well-characterized set of 45 M0 prostate adenocarcinoma and 13 benign tissues. Hypermethylation of EPB41L3 and GSTP1 was compared in 93 cancer tissues by methylation-specific PCR. Expression of 4.1B was further studied by immunohistochemistry.

Results: EPB41L1 and EPB41L3 were significantly downregulated and EPB41L4B was upregulated in cancer tissues. Low EPB41L1 or high EPB41L4B expression were associated with earlier biochemical recurrence. None of the other cortical cytoskeleton genes displayed expression changes, in particular EPB49 and VIL2, despite hints from previous studies. EPB41L3 downregulation was significantly associated with hypermethylation of its promoter and strongly correlated with GSTP1 hypermethylation. Protein 4.1B was detected most strongly in the basal cells of normal prostate epithelia. Its expression in carcinoma cells was similar to the weaker one in normal luminal cells. EPB41L3 downregulation and EPB41L4B upregulation were essentially restricted to the 22 cases with ERG overexpression. Expression changes in EPB41L3 and EPB41L4B closely paralleled those previously observed for the extracellular matrix genes FBLN1 and SPOCK1, respectively.

Conclusions: Specific changes in the cortical cytoskeleton were observed during prostate cancer progression. They parallel changes in the expression of extracellular matrix components and all together appear to be associated with oncogenic ERG overexpression. We hypothesize that these alterations may contribute to the increased invasivity conferred to prostate cancer cells by ERG deregulation.

Citing Articles

1,25-Dihydroxyvitamin D Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line.

Johnson J, Martini R, Yuan Y, Woods-Burnham L, Walker M, Ortiz-Hernandez G Biology (Basel). 2024; 13(5).

PMID: 38785827 PMC: 11118023. DOI: 10.3390/biology13050346.

Extracellular cancer‑associated fibroblasts: A novel subgroup in the cervical cancer microenvironment that exhibits tumor‑promoting roles and prognosis biomarker functions.

Wang Y, Xu M, Yao Y, Li Y, Zhang S, Fu Y Oncol Lett. 2024; 27(4):167.

PMID: 38449793 PMC: 10915806. DOI: 10.3892/ol.2024.14300.

scTIGER: A Deep-Learning Method for Inferring Gene Regulatory Networks from Case versus Control scRNA-seq Datasets.

Dautle M, Zhang S, Chen Y Int J Mol Sci. 2023; 24(17).

PMID: 37686146 PMC: 10488287. DOI: 10.3390/ijms241713339.

Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations.

Kaluzinska-Kolat Z, Kolat D, Kosla K, Pluciennik E, Bednarek A World J Stem Cells. 2023; 15(5):302-322.

PMID: 37342224 PMC: 10277965. DOI: 10.4252/wjsc.v15.i5.302.

Tumor Suppressor 4.1N/ is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC.

Yang Q, Zhu L, Ye M, Zhang B, Zhan P, Li H Front Genet. 2022; 13:805960.

PMID: 35795202 PMC: 9251189. DOI: 10.3389/fgene.2022.805960.

References

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

Chuan Y, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang S, Norstedt G . Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene. 2009; 29(10):1531-42. DOI: 10.1038/onc.2009.442. View

Brooks J, Weinstein M, Lin X, Sun Y, Pin S, Bova G . CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1998; 7(6):531-6. View

Kumar-Sinha C, Tomlins S, Chinnaiyan A . Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008; 8(7):497-511. PMC: 2711688. DOI: 10.1038/nrc2402. View

Wang J, Cai Y, Penland R, Chauhan S, Miesfeld R, Ittmann M . Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate. 2006; 66(15):1641-52. DOI: 10.1002/pros.20474. View

Wong S, Haack H, Kissil J, Barry M, Bronson R, Shen S . Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci U S A. 2007; 104(31):12784-9. PMC: 1924789. DOI: 10.1073/pnas.0705499104. View

Bernkopf D, Williams E . Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets. 2008; 12(7):845-53. DOI: 10.1517/14728222.12.7.845. View

Cookson M, Reuter V, Linkov I, Fair W . Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997; 157(2):673-6. View

Sun C, Robb V, Gutmann D . Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002; 115(Pt 21):3991-4000. DOI: 10.1242/jcs.00094. View

10.

King J, Xu J, Wongvipat J, Hieronymus H, Carver B, Leung D . Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41(5):524-6. PMC: 2898503. DOI: 10.1038/ng.371. View

11.

Tomlins S, Bjartell A, Chinnaiyan A, Jenster G, Nam R, Rubin M . ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009; 56(2):275-86. DOI: 10.1016/j.eururo.2009.04.036. View

12.

Perner S, Mosquera J, Demichelis F, Hofer M, Paris P, Simko J . TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007; 31(6):882-8. DOI: 10.1097/01.pas.0000213424.38503.aa. View

13.

Hoffmann M, Muller M, Engers R, Schulz W . Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol. 2006; 72(11):1577-88. DOI: 10.1016/j.bcp.2006.06.020. View

14.

Wlazlinski A, Engers R, Hoffmann M, Hader C, Jung V, Muller M . Downregulation of several fibulin genes in prostate cancer. Prostate. 2007; 67(16):1770-80. DOI: 10.1002/pros.20667. View

15.

Tan J, Mohandas N, Conboy J . Evolutionarily conserved coupling of transcription and alternative splicing in the EPB41 (protein 4.1R) and EPB41L3 (protein 4.1B) genes. Genomics. 2005; 86(6):701-7. DOI: 10.1016/j.ygeno.2005.08.005. View

16.

Schulz W, Alexa A, Jung V, Hader C, Hoffmann M, Yamanaka M . Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer. 2007; 6:14. PMC: 1797054. DOI: 10.1186/1476-4598-6-14. View

17.

Laprise P, Lau K, Harris K, Silva-Gagliardi N, Paul S, Beronja S . Yurt, Coracle, Neurexin IV and the Na(+),K(+)-ATPase form a novel group of epithelial polarity proteins. Nature. 2009; 459(7250):1141-5. DOI: 10.1038/nature08067. View

18.

Parra M, Gascard P, Walensky L, Gimm J, Blackshaw S, Chan N . Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J Biol Chem. 2000; 275(5):3247-55. DOI: 10.1074/jbc.275.5.3247. View

19.

Calinisan V, Gravem D, Chen R, Brittin S, Mohandas N, Lecomte M . New insights into potential functions for the protein 4.1 superfamily of proteins in kidney epithelium. Front Biosci. 2005; 11:1646-66. DOI: 10.2741/1911. View

20.

Norris J, Chang C, Wittmann B, Kunder R, Cui H, Fan D . The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 2009; 36(3):405-16. PMC: 2788777. DOI: 10.1016/j.molcel.2009.10.020. View